Protease inhibitors and preterm delivery
Autor: | Pat A Tookey, Claire L Townsend, G Favarato, Graham P. Taylor, Claire Thorne, Heather Bailey, Helen Peters |
---|---|
Rok vydání: | 2018 |
Předmět: |
Adult
0301 basic medicine Oncology medicine.medical_specialty Nevirapine Efavirenz Immunology HIV Infections Risk Assessment Lopinavir 17 Psychology And Cognitive Sciences 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Pregnancy Antiretroviral Therapy Highly Active Virology Internal medicine medicine Humans Immunology and Allergy Protease inhibitor (pharmacology) 030212 general & internal medicine Pregnancy Complications Infectious Darunavir Ritonavir business.industry Infant Newborn virus diseases HIV Protease Inhibitors 11 Medical And Health Sciences Odds ratio 06 Biological Sciences 030112 virology United Kingdom Atazanavir Infectious Diseases Anti-Retroviral Agents chemistry Premature Birth Female business Ireland medicine.drug |
Zdroj: | AIDS. 32:243-252 |
ISSN: | 0269-9370 2007-2015 |
DOI: | 10.1097/qad.0000000000001694 |
Popis: | Background Questions remain regarding preterm delivery (PTD) risk in HIV-infected women on antiretroviral therapy (ART), including the role of ritonavir (RTV)-boosted protease inhibitors, timing of ART initiation and immune status. Methods We examined data from the UK/Ireland National Study of HIV in Pregnancy and Childhood on women with HIV delivering a singleton live infant in 2007-2015, including those pregnancies receiving RTV-boosted protease inhibitor-based (n = 4184) or nonnucleoside reverse transcriptase inhibitors-based regimens (n = 1889). We conducted logistic regression analysis adjusted for risk factors associated with PTD and stratified by ART at conception and CD4 cell count to minimize bias by indication for treatment and to assess whether PTD risk differs by ART class and specific drug combinations. Results Among women conceiving on ART, lopinavir/RTV was associated with increased PTD risk in those with CD4 cell count 350 cells/μl or less [odds ratio 1.99 (1.02, 3.85)] and with CD4 cell count more than 350 cells/μl [odds ratio 1.61 (1.07, 2.43)] vs. women on nonnucleoside reverse transcriptase inhibitors-based (mainly efavirenz and nevirapine) regimens in the same CD4 subgroup. Associations between other protease inhibitor-based regimens (mainly atazanavir and darunavir) and PTD risk were complex. Overall, PTD risk was higher in women who conceived on ART, had low CD4 cell count and were older. No trend of association of PTD with tenofovir or any specific drug combinations was observed. Conclusion Our data support a link between the initiation of RTV-boosted/lopinavir-based ART preconception and PTD in subsequent pregnancies, with implications for treatment guidelines. Continued monitoring of PTD risk is needed as increasing numbers of pregnancies are conceived on new drugs. |
Databáze: | OpenAIRE |
Externí odkaz: |